Eternal shares in focus today after Blinkit's food licence suspended by Maharashtra FDA in Pune
By Aditya Bhagchandani Published on June 10, 2025, 09:04 IST
Shares of Eternal Ltd. were in focus on Tuesday after reports emerged that Maharashtra's Food and Drug Administration (FDA) had suspended the food license of Blinkit in Pune's Balewadi area due to multiple regulatory violations, as reported by The Economic Times .
According to the report, a June 5 investigation by the Maharashtra FDA revealed that the Blinkit-operated facility, managed by M/s Energy Darkstore Services near Mitcon College in Balewadi, lacked a valid Food Safety and Standards Authority of India (FSSAI) license required for producing, distributing, or selling food items. In addition to licensing gaps, serious food safety lapses were observed, including improperly stored food items on the floor and missing pest control audits.
The FDA acted under Section 31(1) of the Food Safety and Standards Act, 2006, suspending the facility's food business licence until the proper authorisation is obtained.
This action follows rising scrutiny of dark store operations across India amid growing concerns over food hygiene and regulatory compliance. Blinkit has not yet responded to queries regarding the suspension.
The development has sparked renewed market attention toward Eternal Ltd., which is believed to have exposure or links to service providers in the last-mile and food retail space.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
Business Upturn
3 hours ago
- Business Upturn
Bajaj Finserv appoints Lakshmi Iyer as Group President – Investments, effective August 1
By Aditya Bhagchandani Published on June 10, 2025, 09:41 IST Bajaj Finserv Limited has announced the appointment of Lakshmi Iyer as Group President – Investments, effective August 1, 2025. The development was disclosed in an official filing to the BSE and NSE dated June 10 under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. Lakshmi Iyer brings with her 27 years of experience in the financial services industry, having worked extensively in wealth advisory, strategy, and product solutions across fixed income, real estate, and alternative assets. Known for her expertise in deal execution and fund management, she has led high-performance teams in the investment space. She holds an MBA in Finance from Narsee Monjee Institute of Management Studies and was recognized by Asian Investor as one of Asia's 25 most influential women in asset management. This strategic appointment reflects Bajaj Finserv's continued focus on strengthening its leadership as it scales up operations across its financial services verticals. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Markolines bags Rs 16.75 crore work orders from Vadodara Kim Expressway
By Aditya Bhagchandani Published on June 10, 2025, 10:22 IST Shares of Markolines Pavement Technologies Limited may be in focus on Tuesday after the company announced receipt of two work orders worth Rs 16.75 crore (inclusive of GST) from Vadodara Kim Expressway Pvt. Ltd. The contracts are for rain cut repair works at the project site and are to be executed by July 31, 2025. According to the company's regulatory filing dated June 10, 2025, the first work order is valued at Rs 13.81 crore, and the second at Rs 2.94 crore. Both orders are from a domestic entity, and there is no promoter or related party involvement in the awarding of these contracts. The company emphasized that the orders are in the ordinary course of business and fall under the SEBI Listing Obligations and Disclosure Requirements (LODR) norms for material developments. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
